title: Update on antithrombotic therapy for stroke prevention in atrial fibrillation.
abstract: Atrial fibrillation (AF) is the most common cardiac arrhythmia in the elderly, affecting 1 in 20 adults over the age of 70 years. Stroke is a major yet highly preventable complication of AF, and the strokes related to AF often are disabling and fatal. Warfarin is the treatment of choice in high-risk patients with AF, and its superior efficacy over aspirin for preventing stroke in these patients is widely recognized. However, several eligible patients with AF are not being treated with warfarin or are being treated inadequately, largely because of concerns regarding the attendant strict monitoring, drug interactions, and risk of major bleeding. As such, alternative antithrombotic therapies that can rival or exceed the efficacy of warfarin, yet compare favorably with its administration and side effect profile, are being sought. One such strategy, the use of a combination antiplatelet regimen, for stroke prevention in high-risk patients with nonvalvular AF was investigated recently in two clinical trials. This article reviews the role of combination antiplatelet regimens in stroke prevention for patients with AF. Other therapies discussed include oral anticoagulation, single antiplatelet therapies, oral anticoagulation plus antiplatelet treatment, direct thrombin inhibitors, and factor Xa inhibitors.
authors.affiliation: Department of Neurology, University of California, Los Angeles, 710 Westwood Plaza, Suite 1-240, Los Angeles, CA 90095 USA.
authors.forename: Hermelinda G
authors.initials: HG
authors.lastname: Abcede
authors.forename: Bruce
authors.initials: B
authors.lastname: Ovbiagele
references.citation: Chest. 2008 Jun;133(6 Suppl):546S-592S
references.pmid: 18574273
references.citation: Ann Intern Med. 2007 Jun 19;146(12):857-67
references.pmid: 17577005
references.citation: Lancet. 2006 Jun 10;367(9526):1903-12
references.pmid: 16765759
references.citation: Lancet. 1996 Sep 7;348(9028):633-8
references.pmid: 8782752
references.citation: Lancet. 2008 Jan 26;371(9609):315-21
references.pmid: 18294998
references.citation: BMJ. 2009 Dec 23;339:b5216
references.pmid: 20032065
references.citation: Stroke. 1991 Aug;22(8):983-8
references.pmid: 1866765
references.citation: Am Heart J. 1977 Jul;94(1):101-11
references.pmid: 326013
references.citation: N Engl J Med. 2009 Sep 17;361(12):1139-51
references.pmid: 19717844
references.citation: J Am Coll Cardiol. 2004 Oct 19;44(8):1557-66
references.pmid: 15489085
references.citation: JAMA. 2002 Nov 20;288(19):2441-8
references.pmid: 12435257
references.citation: Lancet. 1993 Nov 20;342(8882):1255-62
references.pmid: 7901582
references.citation: Blood Coagul Fibrinolysis. 1994 Feb;5(1):51-7
references.pmid: 8180338
references.citation: N Engl J Med. 1996 Aug 22;335(8):540-6
references.pmid: 8678931
references.citation: Ann Intern Med. 1999 Oct 5;131(7):492-501
references.pmid: 10507957
references.citation: Stroke. 2007 Mar;38(3):874-80
references.pmid: 17255547
references.citation: N Engl J Med. 2009 May 14;360(20):2066-78
references.pmid: 19336502
references.citation: Stroke. 2006 Feb;37(2):577-617
references.pmid: 16432246